Spots Global Cancer Trial Database for GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Official Title: A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Study ID: NCT01480583
Study Description
Brief Summary: The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from breast cancer. For patients with HER2 positive metastatic breast cancer, GRN1005 will be assessed in combination with Trastuzumab (Herceptin®) as per standard-of-care practice. In addition, this study will evaluate the ability of 18F-FLT to determine if the amount of change in the uptake in the brain metastases from breast cancer after GRN1005 treatment, correlates with intra-cranial response (for patients enrolled at NCI).
Detailed Description: Please see Brief Summary section.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ingalls Memorial Hospital, Harvey, Illinois, United States
NCI, Rockville, Maryland, United States
Contact Details
Name: Betty Lawrence
Affiliation: Angiochem Inc
Role: STUDY_DIRECTOR
Name: Nancy Lin, MD
Affiliation: Dana-Farber Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Susan Bates, MD
Affiliation: National Cancer Institute (NCI)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
